View in EDS

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

Saved in:
Bibliographic Details
Title: Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Authors: Gebhart, G.1 geraldine.gebhart@bordet.be, Lamberts, L. E.2, Wimana, Z.1, Garcia, C.1, Emonts, P.1, Ameye, L.1, Stroobants, S.3, Huizing, M.3, Aftimos, P.1, Tol, J.4, Oyen, W. J. G.4, Vugts, D. J.5, Hoekstra, O. S.5, Schröder, C. P.2, der Houven van Oordt, C. W. Menke-van5, Guiot, T.1, Brouwers, A. H.2, Awada, A.1, de Vries, E. G. E.2, Flamen, P.1
Source: Annals of Oncology. Apr2016, Vol. 27 Issue 4, p619-624. 6p. 1 Diagram, 1 Graph.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdv577